跳至主要内容
临床试验/NCT03866460
NCT03866460已完成不适用

Determination of Hearing Status in Children Receiving Intra-Arterial Carboplatin for Intraocular Retinoblastoma

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年3月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Estimate the incidence of hearing loss

研究概览

简要总结

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
3 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent indicating awareness of the investigational nature of the protocol.
  • Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy.
  • Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants

排除标准

  • Children with known and documented preexisting hearing loss.

结局指标

主要结局

Estimate the incidence of hearing loss

时间窗: 1 year

will be defined as a \>10 db loss from baseline in any frequency, based on the lower threshold of the American Speech and Hearing Associations (ASHA) hearing change criteria. For children unable to cooperate for an audiogram, the DPOAE will be the primary measurement.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验